Table 1 Study characteristics of included case reports
Author (Year) | Age (Years)/ Gender (M/F) | Co-morbidity | Vaccination Type | Doses |
|---|---|---|---|---|
Tishler et al. (2006) | 68 M | Hypertension | Vaxigrip™ | NR |
Mamori et al. (2008) | 75 F | Primary Biliary Cirrhosis | Influenza HA Vaccine ‘Kitaken’ | NR |
Kelton et al. (1981) | 38 M | COPD, Bronchiectasis | NR | NR |
Wan Jamaludin et al. (2018) | 31 F | Hodgkin Lymphoma | 1 | |
Shlamovitz et al. (2013) | 50 M | NR | NR | 1 |
Ikegame et al. (2006) | 19 F | Acute lymphoblastic leukaemia | 1 | |
Almohammadi et al. (2019) | 68 M | Hepatitis C, prediabetes, hypertriglyceridemia | NR | 3 |
Hamiel et al. (2016) | 4.5 M | NR | Fluarix (manufactured by GlaxoSmithKline Biologicals, Dresden, Germany) | 3 |
Mantadakis et al. (2010) | 3 M | NR | (Vaxigrip, Sanofi Pasteur SA, Lyon, France) | 2 |
Nagasaki et al. (2016) | 81 F 75 F 87 F | NR | NR | NR |
Ohta et al. (2022) | 88 M | Stroke, Hypertension. Dyslipidaemia | NR | NR |